Claims
- 1. A compound of the formula ##STR7## wherein R.sub.1 is straight or branched alkyl of 1 to 6 carbon atoms, hydroxy(alkyl of 1 to 4 carbon atoms), mono- or di-(alkoxy of 1 to 3 carbon atoms)(alkyl of 1 to 3 carbon atoms), (alkyl of 1 to 3 carbon atoms)thio(alkyl of 1 to 2 carbon atoms), (alkoxy of 1 to 2 carbon atoms)(alkyl of 1 to 3 carbon atoms)thio(alkyl of 1 to 3 carbon atoms) or cyano(alkyl of 1 to 3 carbon atoms;
- R.sub.2 and R.sub.3 are each independently hydrogen, alkoxy of 1 to 3 carbon atoms or halogen; and
- Z is imidazol-2-yl or imidazol-4-yl;
- provided, however, that when R.sub.1 is straight or branched alkyl and R.sub.2 and R.sub.3 are hydrogen, Z is imidazol-2-yl; a tautomer thereof, or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 2. A compound of claim 1, where said acid addition salt is formed with maleic, hydrochloric, fumaric or sulfuric acid.
- 3. A compound of claim 1, where the formamidine radical is in the para-position on the benzene ring with respect to Z.
- 4. A compound of claim 3, where
- R.sub.1 is propyl, isopropyl, butyl, sec.butyl, isobutyl, neopentyl, methoxyethyl, dimethoxyethyl, hydroxypropyl, hydroxybutyl, methylthioethyl, ethylthioethyl, cyanoethyl or ethoxymethyl-thio-ethyl;
- R.sub.2 and R.sub.3 are each independently hydrogen, methoxy, bromine, chlorine or fluorine; and
- Z is imidazol-2-yl or imidazol-4-yl;
- provided, however, that when R.sub.1 is propyl, isopropyl, butyl, sec.butyl, isobutyl or neopentyl and R.sub.2 and R.sub.3 are hydrogen, Z is imidazol-2-yl; a tautomer thereof, or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 5. A compound of claim 1, which is N-(2-methoxyethyl)-N'-[4-(imidazol-4-yl)-phenyl]formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 6. A compound of claim 1, which is N-(2-hydroxy-propyl)-N'-[4-(imidazol-4-yl)-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 7. A compound of claim 1, which is N-(2-methyl-thio-ethyl)-N'-[4-(imidazol-4-yl)-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 8. A compound of claim 1, which is N-(2-ethoxymethylthioethyl)-N'-[4-(imidazol-4-yl)-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 9. A compound of claim 1, which is N-(2-cyano-ethyl)-N'-[4-(imidazol-4-yl)-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 10. A compound of claim 1, which is N-propyl-N'-[4-(imidazol-4-yl)-2-methoxy-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 11. A compound of claim 1, which is N-propyl-N'-[4-(imidazol-4-yl)-2-bromo-phenyl]-formamidine or a non-toxic, pharmacologically acceptable acid addition salt thereof.
- 12. An antiulcerogenic and gastric acid secretion inhibiting pharmaceutical composition consisting essentially of an inert pharmaceutical carrier and an effective antiulcerogenic and gastric acid secretion inhibiting amount of a compound of claim 1.
- 13. The method of treating gastric ulcers and inhibiting gastric acid secretion in a warm-blooded animal in need thereof, which comprises perorally or parenterally administering to said animal an effective antiulcerogenic and gastric acid secretion inhibiting amount of a compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
21331 A/82 |
May 1982 |
ITX |
|
Parent Case Info
This is a continuation-in-part of copending application Ser. No. 491,367, filed May 4, 1983, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4386099 |
Cereda et al. |
May 1983 |
|
4438127 |
Durant et al. |
Mar 1984 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
1296544 |
Nov 1972 |
GBX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
491367 |
May 1983 |
|